Drug intelligence / Profile preview

Saypha MagIQ

Development stage: Unknown
Lead developer: Croma-Pharma
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Intradermal

Overview

**Saypha MagIQ** is an injectable hyaluronic acid (HA) dermal filler approved by the U.S. FDA for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over 21. Developed by **Croma-Pharma GmbH** using proprietary **MACRO Core Technology**, it forms a stable 3D HA matrix that enables consistent gel distribution, predictable injection force, and natural-looking results across all Fitzpatrick skin types. FDA approval was based on a pivotal 270-patient noninferiority trial (NCT03990883) demonstrating efficacy and safety comparable to controls, with 48-week follow-up.[1][5]

Brand names: Saypha MagIQObagi saypha MagIQ

Beyond the preview

Go deeper on Saypha MagIQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saypha MagIQ.

Explore the full profile